Evidence map›Paper›PMID 41012614›Full record

ArticleViruses2025

Seroprevalence of Neutralizing Antibodies in Healthy Adults, in Mexico, Against Human and Simian Adenovirus Types.

Raúl E López, Margarita Valdés Alemán, Jesús M Torres-Flores, Yordanis Pérez-Llano, David Alejandro Cabrera Gaytán, Clara Esperanza Santacruz Tinoco, Julio Elias Alvarado Yaah, Yu Mei Anguiano Hernández, Bernardo Martínez Miguel, José Esteban Muñoz Medina and 4 more

Abstract read
In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Raúl E LópezCentro de Investigación en Dinámica Celular, Instituto de Investigación en Ciencias Básicas y Aplicadas, Universidad Autónoma del Estado de Morelos, Cuernavaca 62209, Mexico.
Margarita Valdés AlemánCentro de Investigación en Dinámica Celular, Instituto de Investigación en Ciencias Básicas y Aplicadas, Universidad Autónoma del Estado de Morelos, Cuernavaca 62209, Mexico.ORCID 0000-0002-3020-128X
Jesús M Torres-FloresLaboratorio Nacional de Vacunología y Virus Tropicales, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México 11340, Mexico.ORCID 0000-0002-2194-521X
Yordanis Pérez-LlanoCentro de Investigación en Dinámica Celular, Instituto de Investigación en Ciencias Básicas y Aplicadas, Universidad Autónoma del Estado de Morelos, Cuernavaca 62209, Mexico.
David Alejandro Cabrera GaytánCoordinación de Calidad de Insumos y Laboratorios Especializados, Instituto Mexicano del Seguro Social, Ciudad de México 07760, Mexico.ORCID 0000-0001-5314-4786
Clara Esperanza Santacruz TinocoCoordinación de Calidad de Insumos y Laboratorios Especializados, Instituto Mexicano del Seguro Social, Ciudad de México 07760, Mexico.
Julio Elias Alvarado YaahCoordinación de Calidad de Insumos y Laboratorios Especializados, Instituto Mexicano del Seguro Social, Ciudad de México 07760, Mexico.ORCID 0000-0002-7230-9045
Yu Mei Anguiano HernándezCoordinación de Calidad de Insumos y Laboratorios Especializados, Instituto Mexicano del Seguro Social, Ciudad de México 07760, Mexico.
Bernardo Martínez MiguelCoordinación de Calidad de Insumos y Laboratorios Especializados, Instituto Mexicano del Seguro Social, Ciudad de México 07760, Mexico.
José Esteban Muñoz MedinaCoordinación de Calidad de Insumos y Laboratorios Especializados, Instituto Mexicano del Seguro Social, Ciudad de México 07760, Mexico.ORCID 0000-0002-1289-4457
Nancy Sandoval GutiérrezCoordinación de Calidad de Insumos y Laboratorios Especializados, Instituto Mexicano del Seguro Social, Ciudad de México 07760, Mexico.
Ilse Ramos LagunesDirección Técnica y de Investigación, Centro Nacional de la Transfusión Sanguínea, Ciudad de México 17360, Mexico.
José Antonio Arroyo PérezDirección Técnica y de Investigación, Centro Nacional de la Transfusión Sanguínea, Ciudad de México 17360, Mexico.
Ramón A GonzálezCentro de Investigación en Dinámica Celular, Instituto de Investigación en Ciencias Básicas y Aplicadas, Universidad Autónoma del Estado de Morelos, Cuernavaca 62209, Mexico.ORCID 0000-0001-9689-8529

Funding

Secretaría de Ciencia, Humanidades, Tecnología e Innovación F003: C-52-2021; F003: 321211; PRONAII: 303081; PRONAII: 302965
6 · The paper itself

Abstract

Replication-defective adenoviruses are widely used as vectors for vaccines, but their efficacy may be compromised by the prevalence of pre-existing neutralizing antibodies from natural infections or prior vaccination with adenovirus-based vaccines. To overcome these limitations, less common human adenovirus (HAdV) types and simian adenoviruses (SAdV) have been explored as alternative vectors to the widely prevalent HAdV-C5. Despite their importance, there is limited information on the epidemiology of adenovirus immunity in many countries and geographical regions, including Mexico. In this study, we analyzed 2488 serum samples from healthy adults across all 32 states of Mexico to assess the prevalence of both total and neutralizing antibodies against various HAdV types from species A-F, and three related SAdVs. Our findings indicate a high prevalence of neutralizing antibodies against HAdV-C5 and HAdV-C6, with significant cross-reactivity observed among related adenoviruses. Notably, HAdV-D26 exhibited a lower prevalence of neutralizing antibodies, suggesting its potential suitability as a vector for vaccine development in populations with high pre-existing immunity to more common HAdV types. These results provide critical insights for optimizing adenovirus-based vaccine strategies in Mexico.

Indexed as

Adenoviridae InfectionsAdenoviruses, HumanAdenoviruses, SimianAdenovirus Infections, HumanAntibodies, NeutralizingAntibodies, ViralAdolescentAdultCross ReactionsFemaleHealthy VolunteersHumansMaleMexicoMiddle AgedSeroepidemiologic StudiesAntibodies, NeutralizingAntibodies, Viraladenovirus neutralizing antibodiesadenovirus seroprevalenceCOVID-19 vaccineshealthy Mexican adults

Identifiers

PMID41012614
PMCPMC12474060

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.